Literature DB >> 12719574

Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.

Nathan C Gaddis1, Elena Chertova, Ann M Sheehy, Louis E Henderson, Michael H Malim.   

Abstract

Replication of human immunodeficiency virus type 1 (HIV-1) in primary blood lymphocytes, certain T-cell lines (nonpermissive cells), and most likely in vivo is highly dependent on the virally encoded Vif protein. Evidence suggests that Vif acts late in the viral life cycle during assembly, budding, and/or maturation to counteract the antiviral activity of the CEM15 protein and possibly other antiviral factors. Because HIV-1 virions produced in the absence of Vif are severely restricted at a postentry, preintegration step of infection, it is presumed that such virions differ from wild-type virions in some way. In the present study, we established a protocol for producing large quantities of vif-deficient HIV-1 (HIV-1/Delta vif) from an acute infection of nonpermissive T cells and performed a thorough examination of the defect in these virions. Aside from the expected lack of Vif, we observed no apparent abnormalities in the packaging, modification, processing, or function of proteins in Delta vif virions. In addition, we found no consistent defect in the ability of Delta vif virions to perform intravirion reverse transcription under a variety of assay conditions, suggesting that the reverse transcription complexes in these particles can behave normally under cell-free conditions. Consistent with this finding, neither the placement of the primer tRNA3Lys nor its ability to promote reverse transcription in an in vitro assay was affected by a lack of Vif. Based on the inability of this comprehensive analysis to uncover molecular defects in Delta vif virions, we speculate that such defects are likely to be subtle and/or rare.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719574      PMCID: PMC154025          DOI: 10.1128/jvi.77.10.5810-5820.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Identification of a host protein essential for assembly of immature HIV-1 capsids.

Authors:  Concepcion Zimmerman; Kevin C Klein; Patti K Kiser; Aalok R Singh; Bonnie L Firestein; Shannyn C Riba; Jaisri R Lingappa
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

5.  HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.

Authors:  Immanuel Blumenzweig; Lea Baraz; Assaf Friedler; U Helena Danielson; Chaim Gilon; Michael Steinitz; Moshe Kotler
Journal:  Biochem Biophys Res Commun       Date:  2002-04-12       Impact factor: 3.575

6.  Viral and cellular specificities of caprine arthritis encephalitis virus Vif protein.

Authors:  Virginie Seroude; Gilles Audoly; Pablo Gluschankof; Marie Suzan
Journal:  Virology       Date:  2002-01-05       Impact factor: 3.616

7.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

8.  Cell-free transmission of Vif mutants of HIV-1.

Authors:  L Fan; K Peden
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

9.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

10.  Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products.

Authors:  E D Garrett; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  33 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 3.  HIV accessory proteins and surviving the host cell.

Authors:  Jenny L Anderson; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

4.  In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.

Authors:  Mariana Leão de Lima-Stein; Wagner Tadeu Alkmim; Maria Clara de Souza Bizinoto; Luis Fernandez Lopez; Marcelo Nascimento Burattini; Juliana Terzi Maricato; Leila Giron; Maria Cecília Araripe Sucupira; Ricardo Sobhie Diaz; Luiz Mario Janini
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-25       Impact factor: 2.205

5.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

Authors:  Bärbel Schröfelbauer; Darlene Chen; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

8.  Further investigation of simian immunodeficiency virus Vif function in human cells.

Authors:  Nathan C Gaddis; Ann M Sheehy; K Muneer Ahmad; Chad M Swanson; Kate N Bishop; Brigitte E Beer; Preston A Marx; Feng Gao; Frederic Bibollet-Ruche; Beatrice H Hahn; Michael H Malim
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Authors:  Alexandra Kataropoulou; Chiara Bovolenta; Amalia Belfiore; Sonia Trabatti; Anna Garbelli; Simona Porcellini; Rossella Lupo; Giovanni Maga
Journal:  Nucleic Acids Res       Date:  2009-04-15       Impact factor: 16.971

10.  The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Authors:  Nicoletta Casartelli; Florence Guivel-Benhassine; Romain Bouziat; Samantha Brandler; Olivier Schwartz; Arnaud Moris
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.